{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:26Z","timestamp":1793324786937,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.blre.2019.100636","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T18:20:36Z","timestamp":1572718836000},"page":"100636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["New developments in diagnosis, risk assessment and management in systemic amyloidosis"],"prefix":"10.1016","volume":"40","author":[{"given":"Iuliana","family":"Vaxman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archinte.1961.03620030032004","article-title":"\u201cPrimary\u201d Systemic Amyloidosis and Myeloma: discussion of Relationship and Review of 81 Cases","volume":"107","author":"Kyle","year":"1961","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid."},{"issue":"14","key":"10.1016\/j.blre.2019.100636_bb0015","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0020","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"26","key":"10.1016\/j.blre.2019.100636_bb0035","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am J Hemol"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0045","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.bbmt.2019.01.007","article-title":"Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for immunoglobulin light chain amyloidosis: long-term follow-up analysis","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/bloodadvances.2018021261","article-title":"Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details","volume":"3","author":"Sanchorawala","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0055","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia."},{"issue":"15","key":"10.1016\/j.blre.2019.100636_bb0060","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLML.2010.n.027","article-title":"Pitfalls in the diagnosis of primary amyloidosis","volume":"10","author":"Chee","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0085","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2012.03.001","article-title":"What do I need to know about immunoglobulin light chain (AL) amyloidosis?","volume":"26","author":"Dispenzieri","year":"2012","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0100","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2019.100636_bb0110","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0125","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circulation Cardiovascular Imaging"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/01.CIR.63.1.188","article-title":"M-mode and two-dimensional echocardiographic features in cardiac amyloidosis","volume":"63","author":"Siqueira-Filho","year":"1981","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.mayocp.2018.07.025","article-title":"Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure","volume":"94","author":"Chang","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0140","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ehjci\/jew101","article-title":"Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis","volume":"17","author":"Bhatti","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0145","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100636_bb0150","first-page":"42","article-title":"Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy","volume":"18","author":"Papantoniou","year":"2015","journal-title":"Hell J Nucl Med"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0160","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol."},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hemol"},{"issue":"6","key":"10.1016\/j.blre.2019.100636_bb0175","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0180","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4065\/83.11.1226","article-title":"Patterns of neuropathy and autonomic failure in patients with amyloidosis","volume":"83","author":"Wang","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1474-4422(17)30329-0","article-title":"The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes","volume":"16","author":"Terkelsen","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/13506129.2018.1503593","article-title":"Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial","volume":"25","author":"Waddington-Cruz","year":"2018","journal-title":"Amyloid."},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0195","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/art.40162","article-title":"Carpal tunnel biopsy identifying transthyretin amyloidosis","volume":"69","author":"Youngstein","year":"2017","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0200","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0205","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/13506129.2014.935321","article-title":"Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis","volume":"21","author":"Sugiyama","year":"2014","journal-title":"Amyloid."},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0025-6196(12)60634-X","article-title":"Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis","volume":"68","author":"Menke","year":"1993","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0215","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000489297","article-title":"Gastroparesis in a patient with gastric AL amyloidosis","volume":"12","author":"Hoscheit","year":"2018","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.blre.2019.100636_bb0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13256-016-0857-z","article-title":"Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report","volume":"10","author":"Lee","year":"2016","journal-title":"J Med Case Reports"},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0225","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1055\/s-0043-120924","article-title":"Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis","volume":"55","author":"Franck","year":"2017","journal-title":"Z Gastroenterol"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.asjsur.2013.09.013","article-title":"Light-chain amyloidosis presenting with rapidly progressive submucosal hemorrhage of the stomach","volume":"39","author":"Kim","year":"2016","journal-title":"Asian J Surgery"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/13506129.2010.543443","article-title":"Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool","volume":"18","author":"Loustaud-Ratti","year":"2011","journal-title":"Amyloid."},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0240","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.amjmed.2015.04.008","article-title":"Pinch purpura: a cutaneous manifestation of systemic amyloidosis","volume":"128","author":"Agarwal","year":"2015","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.12163","article-title":"Macroglossia as the only presenting feature of amyloidosis due to MGUS","volume":"92","author":"Tsourdi","year":"2014","journal-title":"Euro J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jbspin.2011.09.007","article-title":"AL amyloidosis with temporal artery involvement simulates giant-cell arteritis","volume":"79","author":"Audemard","year":"2012","journal-title":"Joint, Bone, Spine: Revue Du Rhumatisme"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0255","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0260","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0265","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13506120308995256","article-title":"Localized AL amyloidosis of the colon: an unrecognized entity","volume":"10","author":"Kyle","year":"2003","journal-title":"Amyloid."},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-5876(96)01330-4","article-title":"Primary localized nasopharyngeal amyloidosis. A case report","volume":"36","author":"Dominguez","year":"1996","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0275","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.4049\/jimmunol.162.9.5556","article-title":"Organ-specific (localized) synthesis of Ig light chain amyloid","volume":"162","author":"Hamidi Asl","year":"1999","journal-title":"J Immunol (Baltimore, Md: 1950.)"},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.prro.2017.08.003","article-title":"External beam radiation therapy for amyloidosis of the urinary bladder","volume":"8","author":"Cooper","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.blre.2019.100636_bb0285","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-4362.1997.00109.x","article-title":"Primary localized cutaneous amyloidosis: a clinicopathologic study from Saudi Arabia","volume":"36","author":"al-Ratrout","year":"1997","journal-title":"Inter Dermatol"},{"key":"10.1016\/j.blre.2019.100636_bb0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2017.11.001","article-title":"Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis","volume":"72","author":"Garcia","year":"2018","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0295","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00277-009-0857-9","article-title":"Amyloid in bone marrow smears of patients affected by multiple myeloma","volume":"89","author":"Petruzziello","year":"2010","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.blre.2019.100636_bb0300","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fernandez de Larrea","year":"2015","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2019.100636_bb0305","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1159\/000325861","article-title":"Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis","volume":"51","author":"Dhingra","year":"2007","journal-title":"Acta Cytol"},{"issue":"24","key":"10.1016\/j.blre.2019.100636_bb0310","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Euro Heart J"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-015-2549-y","article-title":"Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis","volume":"95","author":"Suzuki","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0320","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med"},{"issue":"9727","key":"10.1016\/j.blre.2019.100636_bb0325","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.blre.2019.100636_bb0330","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0335","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Schonland","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"issue":"18","key":"10.1016\/j.blre.2019.100636_bb0345","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0350","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13506129.2019.1608941","article-title":"Validation of the Boston University staging system in AL amyloidosis","volume":"26","author":"Tomlinson","year":"2019","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0360","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0365","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0370","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","article-title":"Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis","volume":"2","author":"Austin","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.blre.2019.100636_bb0380","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-6649-9-5","article-title":"Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up","volume":"9","author":"Migrino","year":"2009","journal-title":"BMC Medical Physics"},{"issue":"6","key":"10.1016\/j.blre.2019.100636_bb0385","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis","volume":"9","author":"Boynton","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.blre.2019.100636_bb0390","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0395","first-page":"455","article-title":"Prognostic significance of Holter monitor findings in patients with light chain amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0400","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","article-title":"Long-term survival (10 years or more) in 30 patients with primary amyloidosis","volume":"93","author":"Kyle","year":"1999","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0405","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506120500107055","article-title":"Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis","volume":"12","author":"Palladini","year":"2005","journal-title":"Amyloid."},{"issue":"17","key":"10.1016\/j.blre.2019.100636_bb0410","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0415","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0420","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.blre.2019.100636_bb0425","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2019.100636_bb0430","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0435","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/leu.2016.140","article-title":"Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0440","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.14908","article-title":"Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis","volume":"179","author":"Sachchithanantham","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2019.100636_bb0445","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","article-title":"Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability","volume":"111","author":"Bochtler","year":"2008","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0450","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.07.292","article-title":"Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p","volume":"18","author":"Wong","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0460","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41375-018-0308-5","article-title":"Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis","volume":"33","author":"Puig","year":"2018","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0465","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","article-title":"The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0470","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0475","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjmed.2007.02.023","article-title":"Orthostatic hypotension in the elderly: diagnosis and treatment","volume":"120","author":"Gupta","year":"2007","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0480","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiology"},{"issue":"18","key":"10.1016\/j.blre.2019.100636_bb0485","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.blre.2019.100636_bb0490","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100636_bb0495","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0500","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2008-02-138156","article-title":"AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome","volume":"112","author":"Wechalekar","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100636_bb0505","author":"MSMART"},{"issue":"16","key":"10.1016\/j.blre.2019.100636_bb0510","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0515","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0520","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Int Med"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0525","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0530","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0535","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/bmt.2014.115","article-title":"Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up","volume":"49","author":"Parmar","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0540","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2017-06-788729","article-title":"Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation","volume":"130","author":"Browning","year":"2017","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0545","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0550","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2019.100636_bb0555","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/cncr.30051","article-title":"Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis","volume":"122","author":"Gertz","year":"2016","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0560","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3324\/haematol.2014.119198","volume":"100","author":"Hazenberg","year":"2015","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0565","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3324\/haematol.2018.213900","article-title":"Bortezomib based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial","volume":"104","author":"Minnema","year":"2019","journal-title":"Haematologica."},{"issue":"32","key":"10.1016\/j.blre.2019.100636_bb0570","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0575","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0580","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1200\/JCO.2010.31.4161","article-title":"Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection","volume":"29","author":"Bashir","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2014.02.003","article-title":"Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study","volume":"14","author":"Scott","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0590","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0595","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2018.07.010","article-title":"Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation","volume":"24","author":"Afrough","year":"2018","journal-title":"Biol Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0600","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica."},{"issue":"12","key":"10.1016\/j.blre.2019.100636_bb0605","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100636_bb0610","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2019.100636_bb0615","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0620","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100636_bb0625","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/blood.V124.21.4741.4741","article-title":"A phase I dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis","volume":"124","author":"Cohen","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0630","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0635","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0640","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid."},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0645","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0650","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0655","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3324\/haematol.2013.084574","article-title":"Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement","volume":"98","author":"Dinner","year":"2013","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0660","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/13506129.2018.1540410","article-title":"Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis","volume":"25","author":"Kastritis","year":"2018","journal-title":"Amyloid."},{"issue":"15","key":"10.1016\/j.blre.2019.100636_bb0665","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2019.100636_bb0670","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2019.100636_bb0675","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2019.100636_bb0680","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.15541","article-title":"Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis","volume":"183","author":"Sharpley","year":"2018","journal-title":"British J Haematol"},{"issue":"15","key":"10.1016\/j.blre.2019.100636_bb0685","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2019.100636_bb0690","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2019.100636_bb0695","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2018","journal-title":"British J Haematol"},{"key":"10.1016\/j.blre.2019.100636_bb0700","first-page":"1837","article-title":"Daratumumab monotherapy in thirty-two heavily pre-treated patients with advanced systemic light-chain amyloidosis","volume":"130","author":"Kimmich","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2019.100636_bb0705","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica."},{"issue":"24","key":"10.1016\/j.blre.2019.100636_bb0710","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"issue":"11","key":"10.1016\/j.blre.2019.100636_bb0715","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100636_bb0720","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid."},{"issue":"36","key":"10.1016\/j.blre.2019.100636_bb0725","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2019.100636_bb0730","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2019.100636_bb0735","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2019.100636_bb0740","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10428190701684518","article-title":"Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis","volume":"49","author":"Gertz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.blre.2019.100636_bb0745","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.blre.2019.100636_bb0750","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2019.100636_bb0755","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","article-title":"Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1930150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1930150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:58Z","timestamp":1759436638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1930150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":151,"alternative-id":["S0268960X1930150X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100636","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in diagnosis, risk assessment and management in systemic amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100636"}}